Free Trial

Autolus Therapeutics (AUTL) 10K Form and Latest SEC Filings 2026

Autolus Therapeutics logo
$1.64 +0.07 (+4.46%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 +0.06 (+3.35%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Autolus Therapeutics SEC Filings & Recent Activity

Autolus Therapeutics (NASDAQ:AUTL) has submitted 190+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Autolus Therapeutics's financial statements. The most recent filing was a Form 8-K submitted on April 29, 2026.

8-K
Autolus Therapeutics Files Current Report on Apr. 29, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Autolus Therapeutics Files Annual Report on Mar. 27, 2026

The 10-K contains Autolus Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Autolus Therapeutics SEC Filing History

Browse Autolus Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/29/2026 4:28 PM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/15/2026 9:31 AM
Autolus Therapeutics (1730463) Filer
Form DEL AM
04/14/2026 8:21 PM
Autolus Therapeutics (1730463) Filer
Form DEL AM
04/08/2026 3:17 PM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2026 3:39 PM
Autolus Therapeutics (1730463) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/27/2026 7:02 AM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/23/2026 3:54 PM
Autolus Therapeutics (1730463) Issuer
Richardson Ryan (2054449) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:40 PM
Autolus Therapeutics (1730463) Issuer
Piccina Cintia (1907199) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:59 PM
Autolus Therapeutics (1730463) Issuer
Will Matthias (2121979) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:00 PM
Autolus Therapeutics (1730463) Issuer
Leiderman Elisabeth (1842133) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:01 PM
Autolus Therapeutics (1730463) Issuer
BUTITTA CYNTHIA M (1222082) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:58 PM
Autolus Therapeutics (1730463) Issuer
YOUNG WILLIAM D (1217420) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:47 PM
Autolus Therapeutics (1730463) Issuer
Swan Alexander (1976333) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:48 PM
Autolus Therapeutics (1730463) Issuer
Williams Christopher Michael James (2121974) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:48 PM
Autolus Therapeutics (1730463) Issuer
Vann Christopher Andrew (2121963) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:49 PM
Autolus Therapeutics (1730463) Issuer
Pule Martin Anton (2121977) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:50 PM
Autolus Therapeutics (1730463) Issuer
Itin Christian (1362010) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:51 PM
Autolus Therapeutics (1730463) Issuer
Berriman John E (1291964) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:52 PM
Autolus Therapeutics (1730463) Issuer
Iannone Robert (1737329) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:53 PM
Autolus Therapeutics (1730463) Issuer
Bain Linda (1578407) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:54 PM
Autolus Therapeutics (1730463) Issuer
Dolski Robert (1840408) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:55 PM
Autolus Therapeutics (1730463) Issuer
McIlvenny Patrick Paul (2121503) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:55 PM
Autolus Therapeutics (1730463) Issuer
BONNEY MICHAEL W (1219016) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:56 PM
Autolus Therapeutics (1730463) Issuer
Rao Madduri Ravin (1792006) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:57 PM
Autolus Therapeutics (1730463) Issuer
Azelby Robert (1656998) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:45 PM
Autolus Therapeutics (1730463) Issuer
Neville Miranda Suzette (2122016) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:46 PM
Autolus Therapeutics (1730463) Issuer
Driggs Alex (1708997) Reporting
Form 3
Initial statement of beneficial ownership of securities  
02/17/2026 8:51 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Autolus Therapeutics (1730463) Subject
Form SCHEDULE 13G/A
02/13/2026 3:07 PM
Autolus Therapeutics (1730463) Subject
MAK Capital Fund LP (1426156) Filed by
Form SCHEDULE 13G/A
01/26/2026 3:07 PM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/26/2026 3:09 PM
Autolus Therapeutics (1730463) Filer
Form 424B3
01/12/2026 7:37 AM
Autolus Therapeutics (1730463) Filer
Form 424B3
01/12/2026 7:36 AM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/02/2025 4:17 PM
Autolus Therapeutics (1730463) Filer
Form 424B3
12/02/2025 3:49 PM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 5:38 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Autolus Therapeutics (1730463) Subject
Form SCHEDULE 13G
11/14/2025 7:08 AM
Autolus Therapeutics (1730463) Subject
Deep Track Capital, LP (1856083) Filed by
Form SCHEDULE 13G/A
11/12/2025 3:28 PM
Autolus Therapeutics (1730463) Filer
Form 424B3
11/12/2025 7:13 AM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/06/2025 11:22 AM
Autolus Therapeutics (1730463) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
08/12/2025 7:11 AM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/30/2025 8:31 AM
Autolus Therapeutics (1730463) Filer
Form 424B3
06/27/2025 7:47 AM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025 5:36 PM
Autolus Therapeutics (1730463) Subject
MAK Capital Fund LP (1426156) Filed by
Form SCHEDULE 13G
05/15/2025 11:15 PM
Autolus Therapeutics (1730463) Filer
Form EFFECT
05/08/2025 4:08 PM
Autolus Therapeutics (1730463) Filer
Form S-1
Registration statement under Securities Act of 1933  
05/08/2025 7:04 AM
Autolus Therapeutics (1730463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2025 8:00 AM
Autolus Therapeutics (1730463) Subject
Syncona Portfolio Ltd (1725042) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Autolus Therapeutics SEC Filings - Frequently Asked Questions

Autolus Therapeutics (AUTL) has submitted 190+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Autolus Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Autolus Therapeutics's financial statements page.

The most recent filing was a Form 8-K submitted on April 29, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:AUTL) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners